Search details
1.
Discovering dominant tumor immune archetypes in a pan-cancer census.
Cell
; 185(1): 184-203.e19, 2022 01 06.
Article
in English
| MEDLINE | ID: mdl-34963056
2.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
N Engl J Med
; 388(3): 228-239, 2023 01 19.
Article
in English
| MEDLINE | ID: mdl-36652354
3.
Genome-wide association study identifies high-impact susceptibility loci for HCC in North America.
Hepatology
; 2024 Feb 20.
Article
in English
| MEDLINE | ID: mdl-38381705
4.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 401(10391): 1853-1865, 2023 06 03.
Article
in English
| MEDLINE | ID: mdl-37075781
5.
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Future Oncol
; 19(38): 2505-2516, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37671641
6.
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(8): 995-1008, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35798016
7.
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Lancet Oncol
; 23(1): 77-90, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34914889
8.
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
Br J Cancer
; 126(4): 569-575, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34621044
9.
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
J Hepatol
; 76(3): 681-693, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34801630
10.
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.
Oncologist
; 27(10): 874-883, 2022 10 01.
Article
in English
| MEDLINE | ID: mdl-35972334
11.
Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial.
BMC Cancer
; 22(1): 377, 2022 Apr 09.
Article
in English
| MEDLINE | ID: mdl-35397508
12.
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
N Engl J Med
; 379(1): 54-63, 2018 Jul 05.
Article
in English
| MEDLINE | ID: mdl-29972759
13.
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(6): 796-807, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32416072
14.
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
Int J Cancer
; 147(8): 2190-2198, 2020 10 15.
Article
in English
| MEDLINE | ID: mdl-32359091
15.
Systemic therapies for intrahepatic cholangiocarcinoma.
J Hepatol
; 72(2): 353-363, 2020 02.
Article
in English
| MEDLINE | ID: mdl-31954497
16.
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Oncologist
; 25(12): e1825-e1836, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32548867
17.
Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.
Value Health
; 23(5): 551-558, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32389219
18.
Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
J Pathol
; 248(2): 164-178, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30690729
19.
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
Future Oncol
; 16(21): 1525-1536, 2020 Jul.
Article
in English
| MEDLINE | ID: mdl-32491932
20.
Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
Cancer
; 125(18): 3234-3241, 2019 09 15.
Article
in English
| MEDLINE | ID: mdl-31154669